CTOs on the Move

Hillcroft Medical Clinic Assn

www.hillcroftmed.com

 
Hillcroft Medical Clinic Assn is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Houston, TX. To find more information about Hillcroft Medical Clinic Assn, please visit www.hillcroftmed.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

CRH Healthcare

CRH Healthcare is a patient and quality focused urgent care center company focused on delivering the Perfect Patient Experience every time.

Symbiomix Therapeutics

Symbiomix (sim-bye-OH-mix) is a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women`s health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world`s leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences and HBM Partners. The Company`s lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.

Freeda Health

Freeda services the nutritional needs of the community at large as well as vegetarians/vegans, the Celiac community, Kosher consumers, Diabetics, and more...

Rothenberger USA

Rothenberger USA is a Rockford, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.